From: Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder
Treatment | # individuals | # individuals with known response | 2-week response (n, (% of those taking with known response)) | 3-month response (n, (% of those taking with known response)) | Worsening seizures (n, (% of those taking with known response)) | No change (n, (% of those taking with known response)) |
---|---|---|---|---|---|---|
Cannabidiol (Epidiolex) | 19 | 14 (74%) | 4 (29%) | 3 (21%) | 4 (29%) | 6 (43%) |
Non-FDA-approved cannabis derivative | 18 | 4 (19%) | 2 (50%) | 2 (50%) | 1 (25%) | 2 (50%) |